Opportunity Alert – AC-160105-085 – COVANCE-07

Date Sourced: March 22, 2016
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): Moderate
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No

---

Opportunity:
Covance is a full spectrum drug development company providing ED, Central
labs, and Phase IIV
clinical trial mgmt services. It helped develop all top 50 drugs on the
market in 2014; and collaborated on 87% of the 45 new drugs in 2015,
including 100% of oncology drugs. Today Covance generates more safety and
efficacy data than any other drug development company.
Website:
www.covance.com

Summary of Activities/Tasks:
1. March 22, 2016 – Deborah Keller, Covance CEO, was the keynote at CTC.
Her comments highlighted the changes taking place in drug develpment,
including increasing trial complexity with the evolution of new study
designs and data streams. Informatics is what Covance aims to make their
differentiator.

Spoke privately with Deb at length. Took the opportunity to discuss the
work one of our client companies was doing in a dozen Covance trails.
Outlined the CleverCap solution and discussed its application in clinical
trials. Deb noted that CleverCap supports Covance efforts to derive more
informed insights during trials; and support adaptive trial design.

2. March 29, 2016 – Followed-up with Deb via email and sent CleverCap deck.
Highlighted the opportunity for CleverCap to support real-time med
adherence; and directly impact trial outcomes by providing actionable
insights into subject adherence, compound toxicity and protocol compliance.
Deb replied quickly and agreed to share comments and feedback from her
team.

3. April 5, 2016 – Circled back with Deb. Requested suggestions on who I
might meet with to evaluate the potential applications for CleverCap within
Covance studies. Waiting for reply.

---

Forward Statements and Guidance:
Next week we will be reaching out to Mark Matson, Covance Director of Bus
Dev Phase II – IV. The aim will be to get a face-to-face meeting with Mark
and other stakeholders. Target meeting date is late April.

Although Covance is not currently committed to any other competing med
adherence device, we need to be careful not to fall into the RPM category
where LabCorp has recently invested in Vivify.

End.


Return to Listing

IF YOU HAVE QUESTIONS, COMMENTS OR FEEDBACK RELATED TO
THIS OPPORTUNITY ALERT, PLEASE RESPOND USING THE POST
COMMENT FORM.